• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Medicare Advantage Changes At UnitedHealth Have Changed Its Investment Story

    Simply Wall St·10/11/2026 15:43:54
    Listen to the news
    • UnitedHealthcare introduced its 2027 Medicare Advantage plans, highlighting broad access, $0 primary and preventive care visits, and expanded HMO and special needs offerings aimed at supporting varied health needs.
    • The redesign leans heavily into coordinated HMO and Dual Special Needs Plan models while updating the UCard platform. This signals a focus on tighter cost control and targeted benefits rather than broad membership expansion.
    • We will look at how UnitedHealth Group's margin repair narrative lines up with this 2027 Medicare Advantage shift toward HMO and special needs plans.

    Scan how UnitedHealth Group's Medicare Advantage reset compares to other insurers tightening benefits and cost control by reviewing our curated list of 31 resilient stocks with low risk scores.

    UnitedHealth Group Investment Narrative Recap

    To own UnitedHealth Group today, you need to believe management can repair compressed margins while keeping its government book stable. The 2027 Medicare Advantage reset leans into HMOs and special needs plans, which ties directly to that repair effort. The near term swing factor is Medicare profitability, not membership growth, and this redesign mostly reinforces that focus.

    The biggest operational risk still sits in elevated medical cost trends and weaker Medicaid margins weighing on consolidated earnings. A meaningful drop in 4 star rated Medicare Advantage membership adds another pressure point on quality bonuses. The upcoming earnings call on 13 October is the next real test of how much progress is coming through the P&L.

    The most relevant recent development alongside the plan redesign is the expectation that UnitedHealth Group will discontinue Medicare Advantage coverage for roughly 390,000 members. That move concentrates the book in HMO and Dual Special Needs offerings where coordinated care and benefit design can be tighter, which lines up with the margin repair narrative rather than headline membership gains.

    For you as an investor, the question is whether this pruning plus the 2027 product shift can offset rating pressure and medical cost intensity. Execution on Optum Health, AI driven G&A savings and the pharmacy benefits business remains central, but this Medicare Advantage reset is where the near term earnings risk and opportunity are most visible.

    What The 2029 Analyst Setup Implies For UnitedHealth Group

    UnitedHealth Group's analyst case ties the Medicare Advantage reset and Optum execution back to a relatively specific 2029 earnings picture. The consensus view points to revenue of US$502.0b and earnings of US$23.5b in 2029, supported by an assumed 3.7% yearly increase in revenue over the next three years and profit margins moving from 3.1% today to 4.7% in that same timeframe.

    On the earnings side, the gap is sizeable in dollar terms. Analysts are looking for UnitedHealth Group to move from current earnings of US$14.1b to US$23.5b by 2029. That is an earnings increase of about US$9.4b over the period, with the Medicare Advantage margin repair, Optum Health performance and AI driven G&A savings all sitting in the middle of that bridge.

    Valuation assumptions layer on top of those operating forecasts. The analyst framework uses 2029 revenue of US$502.0b and earnings of US$23.5b as the anchors for a projected P/E of 22.0x in that year, compared with about 24.0x today and against an industry P/E quote of 24.3x for US Healthcare. A discount rate of around 7.2% to 7.24% is applied in the simply stated fair value work, and the current consensus price target of US$481.72 is 21.6% above the quoted share price of US$377.83, with individual targets ranging from US$380.0 to US$529.0.

    UnitedHealth Group's narrative projects US$502.0b revenue and US$23.5b earnings by 2029. This requires 3.7% yearly revenue growth and an earnings increase of about US$9.4b from current earnings of US$14.1b.

    Uncover why UnitedHealth Group's fair value indicates a 27% potential upside to its current price, a gap that may not last much longer.

    NYSE:UNH 1-Year Stock Price Chart
    NYSE:UNH 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on UnitedHealth Group leans hard into regulatory and legal risk. The most cautious analysts were working off 2029 revenue of about US$480.0b and earnings of US$22.9b before this Medicare Advantage news, and some anchored price targets near US$380. You can treat this new plan lineup as a prompt to compare those assumptions with your own.

    Explore 11 other UnitedHealth Group fair value estimates, including one that suggests it could be worth just $395.00.

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond UnitedHealth Group?

    Once you have a view on UnitedHealth Group, it often helps to line it up against a wider watchlist. The Simply Wall St Screener can surface opportunities that match your risk tolerance, return expectations and preferred business profiles in a few focused steps.

    • If capital preservation ranks high for you, consider scanning a curated universe of 31 resilient stocks with low risk scores that score well on stability metrics and more resilient fundamentals.
    • Income focused investors can check out companies that combine higher yields with staying power through our screener featuring 8 dividend fortresses that may warrant a closer look.
    • For those hunting for mispriced quality, the screener highlighting 20 high quality undiscovered gems can help you surface lesser known businesses with stronger underlying financials.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.